Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(12):874-875; doi:10.1093/jnci/94.12.874
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 12, 874-875, June 19, 2002
© 2002 Oxford University Press

NEWS

Breaking the Silence: The Rise of Epigenetic Therapy

Ken Garber

Cancer epigenetics is hot. At the annual meeting of the American Association for Cancer Research in April, once-obscure principal investigators were feted by gaggles of admirers and many poster presenters mobbed by the curious. "It’s one of the hottest areas of basic biology," said Paul Workman, Ph.D., director of cancer therapeutics at Cancer Research U.K. in Sutton, England.


Figure Removed (Available Only in the Full Text)
View larger version (131K):
[in this window]
[in a new window]
  		Dr. Paul Workman

 
Workman said he believes that epigenetic gene silencing is as much a driving force in cancer as genetic mutation. "This is just a major, major way in which tumors turn off genes they don’t want expressed," he said.

This statement would have been heresy just a few years ago, but most scientists now accept that remodeling of chromatin is central to cancer. Chromatin consists of proteins called histones, which form nucleosome . . . [Full Text of this Article]

A New Class of Drugs

Silent Treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]